Metabolic traits and surgical outcomes in Turner syndrome patients with heart defects

Turner syndrome, a genetic condition affecting approximately one in every 2,000 to 2,500 live female births, has long been recognized as far more than a chromosomal anomaly defined by short stature and ovarian insufficiency. Girls and women living with the condition carry a constellation of health risks that follow them from childhood into adulthood, including congenital heart defects, progressive dilation of the aorta, and a cluster of metabolic disturbances that elevate the likelihood of diabetes, hypertension, and cardiovascular disease. A new study published in Pediatric Research now offers one of the most detailed looks yet at how these risks interact in a particularly vulnerable subgroup: patients with Turner syndrome who also harbor congenital heart disease. The findings, drawn from a large cohort of surgically treated patients, suggest that metabolic derangements are not merely incidental companions of the syndrome but may be closely entwined with cardiac anatomy, surgical exposure, and early postoperative outcomes.

The research team, led by Huang and colleagues, set out to answer questions that have persisted in the clinical literature for years. Although the association between Turner syndrome and congenital heart disease is well established, with left-sided obstructive lesions such as bicuspid aortic valve, coarctation of the aorta, and partial anomalous pulmonary venous connection appearing at rates far above those seen in the general population, the baseline metabolic profile of these patients and the trajectory of their recovery after cardiac surgery have remained poorly characterized. Most prior studies have either focused on the cardiac phenotype in isolation or examined metabolic complications in adult cohorts without accounting for the presence of structural heart disease. By bringing these two domains together in a single analysis, the investigators hoped to illuminate the mechanisms through which chromosomal, cardiovascular, and metabolic pathology converge.

The clinical significance of this convergence is difficult to overstate. Turner syndrome results from the complete or partial absence of one X chromosome in phenotypic females, and the consequences ripple across nearly every organ system. Patients typically exhibit short stature due to haploinsufficiency of the SHOX gene, primary ovarian failure requiring hormone replacement therapy, renal anomalies, lymphedema, and distinctive skeletal features. But it is the cardiovascular system where the syndrome exacts its heaviest toll. Congenital heart disease affects an estimated 30 to 50 percent of individuals with Turner syndrome, and even in the absence of structural defects, patients face accelerated aortic root dilation, heightened risk of aortic dissection, and premature coronary artery disease. Meanwhile, metabolic disturbances — insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and hypertension — are documented at rates several-fold higher than in age-matched peers.

Against this backdrop, the new study examined a cohort of Turner syndrome patients with congenital heart disease who had undergone surgical correction, characterizing their metabolic features before operation and tracking early postoperative outcomes. The researchers compiled anthropometric measurements, lipid panels, glycemic indices, and markers of insulin resistance alongside detailed cardiac anatomical diagnoses and perioperative data. This design allowed the team to ask whether the metabolic phenotype of Turner patients with structural heart disease differs meaningfully from what has been reported in Turner patients without heart defects, and whether metabolic status influences how patients fare in the critical days and weeks following cardiac surgery.

One of the study’s central observations concerns the interplay between body composition and metabolic risk. Turner syndrome patients are known to have a distinctive body composition profile, characterized by increased visceral adiposity relative to total body mass, elevated waist-to-hip ratios, and a tendency toward central fat accumulation even in individuals of normal weight. This “thin on the outside, fat on the inside” phenotype predisposes patients to insulin resistance that is often underestimated by standard body mass index screening. The new findings reinforce the concern that children and adolescents with Turner syndrome and congenital heart disease may already manifest early metabolic abnormalities — elevated triglycerides, reduced high-density lipoprotein cholesterol, impaired glucose tolerance — at ages when preventive intervention could still alter their lifetime trajectory.

The growth hormone therapy widely used to treat short stature in Turner syndrome adds another layer of metabolic complexity. Growth hormone is a counter-regulatory hormone that antagonizes insulin action, and while treatment at standard doses is generally considered metabolically safe, the combination of growth hormone exposure, estrogen replacement, and underlying congenital heart disease creates a metabolic milieu that clinicians must navigate carefully. The study’s baseline characterization provides a reference point against which the metabolic effects of these therapies can be judged in patients undergoing cardiac surgery, a population in whom hormonal regimens are often adjusted perioperatively with limited evidence to guide decision-making.

Beyond the metabolic portrait, the study’s analysis of early postoperative outcomes carries immediate practical implications for surgical and intensive care teams. Cardiac surgery triggers a well-described metabolic stress response: cortisol and catecholamine levels surge, insulin resistance deepens, and hyperglycemia frequently develops even in patients with no prior glycemic abnormality. In patients who begin surgery already insulin resistant, this stress response can be amplified, and postoperative hyperglycemia has been linked in numerous studies to increased rates of wound infection, arrhythmia, prolonged mechanical ventilation, and longer intensive care unit stays. The findings in Turner syndrome patients with congenital heart disease suggest that clinicians should view these patients as a metabolically vulnerable group in whom perioperative glycemic management, nutritional support, and monitoring for metabolic complications deserve heightened attention.

The connection between congenital heart disease itself and metabolic derangement adds further intrigue. Children born with structural heart defects, particularly obstructive left-sided lesions, often experience chronic low cardiac output, reduced exercise tolerance, and altered growth patterns that can shape metabolic development long before surgical correction. Coarctation of the aorta, one of the signature lesions of Turner syndrome, produces chronic upper-body hypertension that may predispose to endothelial dysfunction and accelerated vascular aging. When this vascular burden is superimposed on the chromosomal predisposition to insulin resistance and dyslipidemia, the resulting cardiometabolic risk profile may exceed the simple sum of its parts. The study’s integrated characterization of anatomy and metabolism within the same cohort provides a rare opportunity to begin disentangling these contributions.

The implications extend into the adult transition period, which has long been identified as a danger zone for Turner syndrome care. Girls with the condition are typically managed intensively in childhood through multidisciplinary clinics that coordinate growth hormone therapy, cardiology surveillance, and endocrine monitoring. But as patients reach adolescence and young adulthood, follow-up often fragments, and metabolic screening — like cardiac imaging — is frequently performed less diligently than guidelines recommend. Adult cardiologists may focus on aortic surveillance while overlooking lipid panels and glucose tolerance, while endocrinologists may manage hormone replacement without adequate attention to the cardiovascular context. The new evidence that metabolic features correlate with postoperative outcomes offers a concrete clinical rationale for keeping metabolism at the center of care across the lifespan, rather than treating it as a secondary concern.

It is worth emphasizing what the study does and does not establish. The findings characterize associations within a surgical cohort and cannot, by themselves, prove that metabolic abnormalities cause adverse postoperative outcomes or that correcting metabolic disturbances before surgery would improve recovery. Causal inference in this domain would require longitudinal designs, ideally beginning in infancy and following patients through surgical intervention and beyond, with careful adjustment for confounders such as age at surgery, lesion type, surgical technique, and hormonal treatment history. The authors’ work nonetheless establishes an evidentiary foundation for such studies and provides clinically actionable descriptive data in a population that has historically been underrepresented in cardiac surgical research.

The broader scientific context makes the study timely. Over the past decade, researchers have increasingly recognized that congenital heart disease is not a condition that ends at surgical correction but a lifelong cardiovascular syndrome with metabolic, neurodevelopmental, and vascular dimensions. Simultaneously, Turner syndrome specialists have pushed for earlier and more aggressive cardiometabolic screening, citing evidence that women with the condition die from cardiovascular causes at rates far exceeding background risk and at strikingly young ages. The convergence of these two research currents — one centered on the long-term consequences of congenital heart surgery, the other on the systemic manifestations of sex chromosome aneuploidy — makes the present study a natural and important synthesis.

For families of girls with Turner syndrome and congenital heart disease, the message emerging from this research is one of vigilance rather than alarm. The study underscores that routine metabolic evaluation — lipid profiles, fasting glucose or hemoglobin A1c, and assessment of body composition — should be considered a standard component of cardiac care in this population, both before and after surgery. For clinicians, the findings argue for perioperative protocols that anticipate metabolic stress and monitor glycemic control with particular care in Turner patients. And for researchers, the work opens a path toward interventional trials testing whether early metabolic optimization can translate into better surgical outcomes and longer, healthier lives for a group of patients who have waited far too long for evidence built around their unique biology.

p class=”c-bibliographic-information__citation”>Huang, Y., Luo, S., Qi, Y. et al. Metabolic features and postoperative outcomes in Turner syndrome with congenital heart disease. Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05450-1